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The Escherichia coli glucuronylsynthase 
promoted synthesis of steroid glucuronides:  
improved practicality and broader scope† 
Paul Ma, Nicholas Kanizaj, Shu-Ann Chan, David L. Ollis and  
Malcolm D. McLeod* 
A library of steroid glucuronides was prepared using the glucuronylsynthase derived from Escherichia 
coli -glucuronidase, followed by purification using solid-phase extraction. A representative range of 
steroid substrates were screened for synthesis on the milligram scale under optim ised conditions with 
conversions dependent on steroid substitution and stereochemistry. Epiandrosterone (3-hydroxy-5-
androstane-17-one) provided the highest conversion of 90% (84% isolated yield). The previously 
unreported glucuronide conjugates of methandriol (17-methylandrost-5-ene-3,17-diol), cholest-5-
ene-3,25-diol and the designer steroid trenazone (17-hydroxyestr-4,9-dien-3-one) were prepared on a 
multi-milligram scale suitable for characterisation by 1H and 13C NMR spectroscopy. The glucuronide 
conjugate of d5-etiocholanolone (2,2,3,4,4-d5-3-hydroxy-5-androstane-17-one), a target developed by 
the World Anti-Doping Agency as a certified reference material, was also prepared on a milligram scale. 
The improved E. coli glucuronylsynthase method provides for the rapid synthesis and purification of 
steroid glucuronides on a scale suitable for a range of analytical applications.  
INTRODUCTION  
The conjugation of glucuronic acid to an acceptor in phase II 
metabolism is a major pathway for the excretion of endogenous 
and exogenous substances in mammalian systems. Glucuronide 
conjugates 1 (Scheme 1) thus play an important role in various 
fields such as pharmacology,1,2 sports drug testing,3,4 and 
detection of agricultural residues in the environment.5 In 
addition, glucuronides have been used in linkers for targeted 
delivery of cytotoxic agents coupled to monoclonal 
antibodies,6,7 as well as in pro-drugs, which use the body’s 
glucuronidase enzymes to unmask bioactive species.1,8,9 
 There have been many protocols developed for the synthesis 
of glucuronides and these fall under two broad approaches: 
chemical or enzymatic (Scheme 1). The chemical approach, 
that includes the Koenigs–Knorr glycosylation,10 and more 
modern variants, is still the most widely-used method for 
glucuronide synthesis.1,11 However, it can result in the 
production of ortho ester or acyl transfer side-products that 
serve to reduce the yield and complicate purification of the 
desired glucuronide.1,11 In addition, the need for water-sensitive 
activators and glycosyl donors, and the requirement for 
protecting groups makes small-scale synthesis for analytical 
purposes challenging. 
 The enzymatic approach consists of two major methods, the 
first of which utilises mammalian uridine 5'-diphospho-
glucuronosyltransferase (UGT) enzyme family to perform the 
glucuronylation in a single step.12–15 This method has the 
advantage of avoiding protecting groups, but employs a 
sensitive and expensive uridine 5'-diphosphoglucuronic acid 
donor and requires expression of the membrane-bound UGT 
enzymes.16 Difficulties in the expression and purification of 
UGTs mean that animal sacrifice is often used to obtain 
sufficient quantities of enzyme for synthesis, which gives rise 
to additional ethical considerations.12–14 
 The second enzymatic method developed by the McLeod 
group employs the glucuronylsynthase derived from wild-type 
E. coli -glucuronidase.17,18 The glucuronylsynthase is derived 
by single-point mutation of the wild-type enzyme, which 
disables glycosyl hydrolase activity but allows for glycoside 
synthesis when used in combination with a synthetically-
derived -D-glucuronyl fluoride 2 donor.19,20 This method also 
performs glucuronylation in a single step but has some added 
advantages over the UGT-based approach in that the E. coli 
glucuronylsynthase is a soluble bacterial enzyme that is readily 
expressed and purified and the -D-glucuronyl fluoride 2 
substrate is readily accessible in four synthetic steps from 
D-glucose. 
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 Steroid glucuronides are an important class of compounds 
in the field of sports drug testing, with many endogenous and 
exogenous steroids excreted primarily as glucuronide 
conjugates.21 As a result, significant work has been undertaken 
on both the synthesis and analysis of steroid 
glucuronides.13,14,22,23 In previous work we outlined a three-step 
approach based on the temporary introduction of solubilising 
substituents for the glucuronylsynthase-mediated synthesis of 
steroid glucuronides.17 Although effective, the addition and 
deletion of solubilising substituents proved somewhat unwieldy 
and lacking in generality. In this paper we report on the 
development of an improved method for the single-step 
glucuronylsynthase-mediated synthesis and purification of 
steroid glucuronides on a scale suitable for a range of analytical 
applications. 
 
Scheme 1 Preparation of glucuronide conjugates. 
Results and discussion 
The glucuronylation protocol developed has three main 
components: the glucuronylsynthase enzyme, the synthetically-
derived -D-glucuronyl fluoride 2 donor and a suitable 
acceptor alcohol (Scheme 2).17 In this paper the substrates were 
steroidal alcohols of different constitutions and 
stereochemistries. The reactions were carried out in a mixed 
10% v/v tert-butanol/sodium phosphate buffer at pH 7.5 and 
37 °C for 2 d. We observed that conducting the reactions in the 
presence of tert-butanol led to a significant increase in steroid 
solubility without the co-solvent serving as a substrate or 
having a deleterious effect on enzyme activity, obviating the 
need for solubilising substituents to obtain reasonable solubility 
and hence useful enzyme-catalysed reaction rates.17 This 
contrasts with the influence of tert-butanol co-solvent (5 or 
10% v/v) on the glucuronylation of 2-phenylethanol that shows 
moderately reduced enzyme activity.17 The wild-type 
-glucuronidase-mediated hydrolysis of para-nitrophenyl -D-
glucuronide also shows reduced activity in the presence of tert-
butanol co-solvent (5 or 10% v/v), albeit with similar long-term 
enzyme stability relative to buffer alone.17 
 
Scheme 2 The glucuronylsynthase protocol. 
 To facilitate the rapid purification of the glucuronide 
product from residual steroidal alcohol, non-volatile salts and 
other reaction components we developed a method based on 
commercially available solid-phase extraction (SPE) cartridges. 
Our SPE purification employed Oasis WAX cartridges 
containing a mixed-mode polymeric/weak anion exchange 
resin. Cartridges were conditioned with methanol and water and 
then loaded with the crude reaction mixture. The cartridge was 
then washed with 2% aqueous formic acid, water and then 
methanol to elute any residual steroidal alcohol substrate. The 
steroidal glucuronide was eluted with saturated aqueous 
ammonium hydroxide in methanol (5% v/v). The target 
glucuronides were afforded in high purity after evaporation of 
the eluant under reduced pressure. The 1H NMR spectra of the 
SPE purified materials so obtained were fully consistent with 
the proposed structures and are reproduced in the Electronic 
Supplementary Information (ESI). Our investigations revealed 
that reactions using 1 mg of steroidal alcohol were readily 
purified using a single 60 mg resin (3 cc) SPE cartridge. Larger 
scale synthesis required purification in parallel or the use of 
larger 500 mg resin (6 cc) cartridges. 
 Given the typically small scale of the synthesis, determining 
the mass of product and hence chemical yield with precision 
was not feasible. To address this we elected to monitor the 
conversion of starting material to product by 1H NMR 
integration. Omitting the methanol wash step in the SPE 
method outlined above resulted in the elution by methanolic 
ammonia of a combined fraction containing both free steroid 
and steroid glucuronide. This was then subjected to 400 or 600 
MHz 1H NMR integration of selected steroidal protons in both 
the starting material and product allowing for the determination 
of reaction conversion as reported in Table 1. For the secondary 
steroidal alcohols studied, glucuronylation typically resulted in  
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Table 1 Synthesis of steroid glucuronides 
aReactions conditions: steroid (1.0 equiv), -D-glucuronyl fluoride (5.0 equiv), E. coli glucuronylsynthase (0.2 mg mL–1), tert-butanol (10% v/v), sodium 
phosphate buffer (50 mM, pH 7.5), 37 °C, 2 d. bDetermined by 400 or 600 MHz 1H NMR integration. cIsolated yield of pure glucuronide for reactions on 5–10 
mg scale. dThe 400 or 600 MHz 1H NMR spectrum is provided in the ESI. eConversion <5% as determined by 400 MHz 1H NMR integration. fThe 150 MHz 
13C NMR spectrum is provided in the ESI. gEluted as a 1.0:1.6:1.1 mixture of 3-mono-, 17-mono- and 3,17-bis-glucuronides as determined by 600 MHz 1H 
NMR integration. 
Entrya Glucuronide product Conv. %b 
(Yield %)c 
 Entrya Glucuronide product Conv. %b 
(Yield %)c 
1 
 
50d 
 
10 
 
36d,f 
(26) 
2 
 
28d 
 
11 
 
90d,f 
(84) 
3 
 
<5e 
 
12 
 
<5e 
4 
 
64d 
 
13 
 
25d 
(20) 
5 
 
8d 
 
14 
 
33d 
6 
 
13d 
 
15 
 
88d,g 
7 
 
12d 
 
16 
 
<5e 
8 
 
87d,f 
(94) 
 
17 
 
20d,f 
(8) 
9 
 
32d,f 
(15) 
 
18 
 
21d,f 
(34) 
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a 0.24–0.31 ppm downfield shift of the oxymethine proton at 
the reaction site, with the anomeric proton showing a coupling 
constant (3J1,2 = 7.7-8.0 Hz) consistent with -glycoside 
formation. For the phenolic substrates estrone and estradiol, 
glucuronylation resulted in a 0.32–0.34 ppm downfield shift of 
the protons ortho to the reaction site, with the anomeric proton 
obscured by water from the deuterated methanol solvent. The 
conversion showed good reproducibility for the glucuronylation 
of dehydroepiandrosterone (87, 90 and 94% conversion, n = 3), 
testosterone (48 and 50%), methandriol (32 and 33%) and 
estrone (29, 30 and 33%), such that we now routinely assess 
enzyme activity by monitoring the small scale reaction 
conversion of dehydroepiandrosterone. In examples where 
larger scale synthesis was conducted (entries 8–11, 13, 17, 18) 
the isolated yields showed reasonable concordance with the 
reported conversions. 
 The glucuronide products 3–20 resulting from a screen of 
eighteen different steroidal alcohols possessing a range of 
different constitutions and stereochemistries are shown in Table 
1. Several trends were evident in the observed conversions with 
steroids possessing 3- or 17-hydroxy groups giving higher 
conversions under the glucuronylation conditions than those 
with 3- or 17-hydroxy groups (cf. entries 1 and 2, 11 and 
12). In addition, 3-hydroxyandrostane derivatives (entries 8–
11) generally gave higher conversions than their 17-hydroxy 
congeners (entries 1, 4–7 and 18), which may be attributed to 
the slightly higher steric bulk resulting from the neighbouring 
C18 methyl group or other unfavourable enzyme-substrate 
interactions. The two steroids with highest conversion were 
dehydroepiandrosterone (entry 8) and epiandrosterone (entry 
11), while stereochemically distinct substrates such as 
etiocholanolone (entry 13) and androsterone (entry 12) were 
less productive. Despite the changes in reactivity, the 
glucuronylation was effective for a wide range of common 3, 5 
and 17 steroidal stereochemistries and substitution patterns. In 
the majority of cases (Table 1), conducting the reaction on a 1–
2 mg scale afforded pure glucuronide on a sufficient scale to 
conduct 400 or 600 MHz 1H NMR analysis. The broad 
substrate scope of this enzyme catalysed synthesis is 
noteworthy but has parallels in the use of wild-type E. coli 
-glucuronidase in analytical applications. During routine 
screening for the presence of steroidal compounds in athlete 
samples, -glucuronidase is employed to hydrolyse the 
combined glucuronide fraction to give free steroids prior to 
derivatisation and analysis by GCMS.24 This protocol relies on 
the promiscuity of the enzyme to catalyse the hydrolysis of the 
wide range of steroid glucuronides present with few 
exceptions.25,26 The glucuronylsynthase enzyme used in this 
study appears to retain analogous promiscuity, albeit with an 
efficacy that depends on steroid substitution patterns. 
 Methyltestosterone (entry 3) was one of three tertiary 
alcohols that were examined, with the corresponding 
glucuronide 5 was obtained in only trace amounts (<5% 
conversion), detectable by mass spectrometry but not 1H NMR. 
This is likely due to the high steric hindrance afforded by both 
the C18 and C20 methyl groups that impede access of the 17-
hydroxy group to the glycosyl donor. This parallels the low 
reactivity observed for methyltestosterone in the Koenigs–
Knorr glycosylation and deprotection sequence, affording a low 
3.5% yield of the methyltestosterone 17-glucuronide.27 Little or 
no reactivity for methyltestosterone glucuronylation is observed 
for recombinant human UGTs and human liver microsomes.15 
Low yields are also reported for glucuronylation using rat liver 
microsomes.13 For methandriol (entry 9), which possesses both 
a secondary 3- and tertiary 17-hydroxy groups, and cholest-
5-ene-3,25-diol (entry 17) which possesses both a secondary 
3- and tertiary 25-hydroxy groups, glucuronylation was 
observed to take place regioselectively at the secondary 
hydroxy group. In both examples a 0.26 ppm downfield shift 
the H3 proton was observed consistent with glucuronylation at 
H3. Estradiol which possesses both phenolic 3- and secondary 
17-hydroxy groups afforded a mixture of 3-mono-, 17-mono- 
and 3,17-bis-glucuronides in an 1.0:1.6:1.1 ratio as determined 
by 600 MHz 1H NMR integration. 
 For some substrates such as androstanolone (entry 6) and 
the cholesterol derivatives (entries 16, 17), solubility posed a 
particular problem that likely contributed to the low conversion 
– for example, only trace amounts of coprostanol 3-glucuronide 
(entry 16) was observed. The co-solvent tert-butanol was used 
to enhance steroid solubility in the aqueous reaction media and 
was able to dissolve the majority of steroid substrates used in 
this study at a final concentration of ~0.69 mM, but for the 
substrates mentioned above only partial dissolution was 
achieved and so the reactions were conducted on the resulting 
saturated solutions. 
 During this study we found that the literature contained 
little NMR characterisation data for several known glucuronide 
products that were prepared in the screen. To redress this, we 
scaled up our syntheses for these substrates, specifically for 
pregnenolone and epiandrosterone (entries 10 and 11), 
obtaining full 1H and 13C NMR data for each. Three of the 
substrates investigated, methandriol, cholest-5-ene-3,25-diol 
and the designer steroid trenazone (entries 9, 17 and 18),28 gave 
rise to previously un-reported glucuronide conjugates 11, 19 
and 20 that were also prepared on a scale suitable for 
characterisation by 1H and 13C NMR spectroscopy. 
 One of the aims of our work was to provide a simple and 
effective alternative protocol for the synthesis of steroid 
glucuronides, in particular for small scale research applications 
where traditional methods of glucuronide synthesis fail or 
encounter significant practical difficulties. One such application 
is the synthesis of glucuronide conjugates from rare and 
expensive deuterated steroids. The deuterated steroid conjugate 
d5-etiocholanolone 3-glucuronide 21 is a compound developed 
by the World Anti-Doping Agency (WADA) as a reference 
material to facilitate the longitudinal monitoring of testosterone 
abuse.29 In our hands a commercially-derived one milligram 
sample of d5-etiocholanolone 22 was converted to the 
corresponding glucuronide 21 conjugate on a sufficient scale to 
conduct 600 MHz NMR analysis (Scheme 3). The resulting 
conjugate showed an absence of the H3 proton signal of the 
non-deuterated counterpart at H 3.81 together with 
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simplification of the aliphatic region from H 1.98–0.98 
consistent with per-deuteration of the A-ring. High-resolution 
mass spectrometry under negative ESI also revealed an ion 
([M – H]–, m/z 470.2800) consistent with the 
d5-etiocholanolone 3-glucuronide 21. 
 The glucuronylation of two additional17,18 non-steroidal 
acceptors was investigated that hints at a wider substrate scope 
for the glucuronylsynthase protocol (Table 2). This resulted in 
the formation 4-methylumbeliferone 7-glucuronide 2330 and 
chloramphenicol 3-glucuronide 24.31 Chloramphenicol 
glucuronide has previously been prepared by UGT-mediated 
synthesis.31 During comparison with the literature data we 
noted that the published 1H NMR data and spectra were 
incorrectly referenced but accounting for this, the data and 
spectra corresponded well with the material produced in this 
work. The regioselectivity of glucuronylation was supported by 
the downfield shift (0.19 and 0.10 ppm) of the H3 protons and a 
HMBC three bond correlation between one H3 proton (4.00 
ppm) and the anomeric carbon (104.2 ppm). Finally, although 
the results of this study have focussed on small scale synthesis 
compatible with rapid SPE purification, we also note that the 
glucuronylsynthase method reported here is readily scalable. In 
previous work the glucuronylsynthase has been used for the 
larger scale synthesis of a testosterone 17-glucuronide 
derivative (72% yield, 54 mg) and 2-phenylethanol glucuronide 
(96% yield, 718 mg).17,18 
 
Scheme 3 Synthesis of d5-etiocholanolone 3-glucuronide 21. 
Conclusion 
A library of steroid glucuronides was prepared using the 
glucuronylsynthase derived from Escherichia coli -
glucuronidase, followed by purification using solid-phase 
extraction. The improved protocol demonstrated broad 
substrate scope, with fifteen out of eighteen substrates 
providing glucuronide conjugate in high purity and on a scale 
suitable for 1H NMR analysis. The method allows for the rapid 
synthesis and purification of glucuronide conjugates on a small 
scale and avoids many of the complications associated with 
traditional chemical or enzymatic approaches. The reliability 
and efficiency of this method is highlighted by the preparation 
of a d5-etiocholanolone 3-glucuronide 21 from a commercially-
derived one milligram sample of the deuterated steroid d5-
etiocholanolone 22. It is envisaged that the E. coli 
glucuronylsynthase system will help meet the future demand 
for glucuronide standards in analytical applications. Further 
engineering, directed to increasing the substrate scope and 
improving the catalytic efficiency of the glucuronylsynthase 
enzyme is in progress and will be reported in due course. 
Table 2 Synthesis of non-steroidal glucuronides 
Entrya Glucuronide product Conv. (%)b 
1 
 
53c 
2 
 
11c,d 
aReactions conditions: acceptor (1.0 equiv), -D-glucuronyl fluoride (5.0 
equiv), E. coli glucuronylsynthase (0.2 mg mL–1), tert-butanol (10% v/v), 
sodium phosphate buffer (50 mM, pH 7.5), 37 °C, 2 d. bDetermined by 400 or 
800 MHz 1H NMR integration. cThe 400 or 800 MHz 1H NMR spectrum is 
provided in the ESI. dThe 800 MHz 2D HSQC and HMBC spectra are 
provided in the ESI.  
Experimental 
Epiandrosterone 3-glucuronide 13.30 Method A (conversion 
by 1H NMR analysis): Epiandrosterone (1.00 mg, 3.44 mol) 
was dissolved in tert-butanol (500 L) and sodium phosphate 
buffer (3.22 mL, 50 mM, pH 7.5). Glucuronylsynthase (0.92 
mL, 1.09 mg mL–1, final concentration 0.2 mg mL−1) and -D-
glucuronyl fluoride 2 (3.89 mg, 18.2 μmol, 5 equiv) dissolved 
in sodium phosphate buffer (365 L, 50 mM) were added and 
the reaction incubated without agitation at 37 °C for 2 days. 
The reaction was then subjected to solid-phase extraction. An 
Oasis WAX SPE cartridge (60 mg, 3 mL) was pre-conditioned 
with methanol (1 mL) and milliQ water (3 mL). The crude 
reaction was loaded onto the cartridge and washed with 
aqueous formic acid (3 mL, 2% v/v), milliQ water (3 mL), and 
finally with saturated aqueous ammonium hydroxide in 
methanol (9 mL, 5% v/v). The appropriate fractions were 
combined and the solvent removed under reduced pressure at 
40 °C to afford a mixture of epiandrosterone and 
epiandrosterone 3-glucuronide with a 90% conversion as 
determined by 600 MHz 1H NMR integration of the H3 
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protons. A copy of the 1H NMR conversion spectrum is 
reproduced in the ESI. 
 Method B (synthesis): The reaction was carried out as for 
method A on a larger scale with epiandrosterone (5.03 mg, 1.73 
mol). The reaction was then subjected to solid-phase 
extraction. An Oasis WAX SPE cartridge (500 mg, 6 mL) was 
pre-conditioned with methanol (5 mL) and milliQ water (15 
mL). The crude reaction was loaded onto the cartridge and 
washed with aqueous formic acid (15 mL, 2% v/v), milliQ 
water (15 mL), methanol (15 mL) to elute free steroid, and 
finally with saturated aqueous ammonium hydroxide in 
methanol (30 mL, 5% v/v) to elute the steroid glucuronide. The 
appropriate fractions were combined and the solvent removed 
under reduced pressure at 40 °C to afford epiandrosterone 
3-glucuronide 13 as a white solid (6.8 mg, 84%). Copies of the 
1H and 13C NMR spectra are reproduced in the ESI. Rf 0.44 
(7:2:1 EtOAc : MeOH : H2O); H (600 MHz, CD3OD) 4.41 
(1 H, d, JH20–H21 8.0, H20), 3.78 (1 H, m, H3), 3.55 (1 H, d, 
JH24–H23 9.5, H24), 3.43 (1 H, t, JH23–H24 ≈ JH23–H22 9.2, H23), 
3.39 (1 H, t, JH22–H23 ≈ JH22–H21 8.9, H22), 3.18 (1 H, t, JH21–H22 
≈ JH21–H20 8.4, H21), 2.43 (1 H, dd, J 19.3, 8.7), 2.06 (1 H, dt, J 
19.3, 9.4) 1.97–1.91 (2 H, m), 1.83 (1 H, m), 1.75–1.49 (7 H, 
m), 1.40–1.28 (5 H, m), 1.23 (1 H, m), 1.15 (1 H, m), 1.06–1.01 
(2 H, m), 0.88 (3 H, s, CH3), 0.87 (3 H, s, CH3), 0.75 (1 H, m); 
C (150 MHz, CD3OD) 224.0 (C17), 176.7 (C25), 101.8 (C20), 
78.5 (C3), 77.8 (C22), 75.4 (C24), 74.9 (C21), 73.7 (C23), 55.8, 
52.6, 45.9, 38.1, 36.8, 36.6, 36.3, 35.1, 32.7, 32.0, 30.2, 29.7, 
22.6, 21.5, 14.1 (CH3), 12.6 (CH3), one carbon overlapping or 
obscured; LRMS (–ESI) m/z: 465 ([M – H]–); HRMS (–ESI) 
m/z: Calcd. for C25H37O8 ([M – H]
–) 465.2488, found 465.2488. 
Abbreviations 
Androstanolone 17-hydroxy-5-androstan-3-one 
Androsterone 3-hydroxy-5-androstan-17-one 
Boldenone 17-hydroxyandrost-1,4-dien-3-one; 
  
Coprostanol 5-cholestan-3-ol 
Dehydroepiandrosterone 3-hydroxyandrost-5-en-17-one 
Epiandrosterone 3-hydroxy-5-androstan-17-one 
Epitestosterone 17-hydroxyandrost-4-en-3-one 
Estradiol estra-1,3,5(10)-triene-3,17-diol 
Estrone 3-hydroxyestra-1,3,5(10)-trien-17-
one 
Etiocholanolone 3-hydroxy-5-androstan-17-one 
d5-Etiocholanolone 2,2,3,4,4-d5-3-hydroxy-5-
androstan-17-one 
Mesterolone 17-hydroxy-1-methyl-5-
androstan-3-one 
Methandriol 17-methylandrost-5-ene-3,17-
diol 
Methyltestosterone 17-hydroxy-17-methylandrost-4-
en-3-one 
Nandrolone 17-hydroxyestr-4-en-3-one 
Pregnenolone 3-hydroxypregn-5-en-20-one 
SPE solid-phase extraction 
Testosterone 17-hydroxyandrost-4-en-3-one 
Trenazone 17-hydroxyestra-4,9-dien-3-one 
UGT uridine 5'-diphosphoglucuronosyl-
transferase 
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